Ann: SuperChem to Commence Sales of wheezo, page-76

Clearly not an issue given they have sold more than 7500 devices thus far...

I would expect the company to capture 5% of the addressable market in Australia of the 2.7m people with asthma...
That would be 135,000 over the next 36 months as a conservative time frame...

thats $16m in annual SaaS revenue along on current multiples for growing SaaS companies low end the small Australian market will give us a 350m market cap if we can show the stickiness of our customers we might be able to get a multiple off 24month SaaS rather than 12 month.

but I'm happy to be on the way with cashflow starting which will surely only grow.

Then we start in Europe at then end of this year which will only grow...

this is even before the US market.